AHA: American Heart Association
Conference Coverage
Cardiac arrests peak with pollution in Japan
PHILADELPHIA –
Conference Coverage
Icosapent ethyl cost effective in REDUCE-IT analysis
PHILADELPHIA – Treatment with the fish-derived drug for CV event reduction is more effective and less costly than placebo.
Conference Coverage
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
Conference Coverage
Colchicine cut post-MI CVD events
PHILADELPHIA – Colchicine fulfilled the promise first seem in CANTOS that anti-inflammatory treatment can reduce cardiovascular disease events.
Conference Coverage
Treating LDL to below 70 reduces recurrent stroke
PHILADELPHIA – Results of TST, a rare cholesterol study in patients with a history of ischemic stroke, explore the benefits of treating to a lower...
Conference Coverage
ISCHEMIA-CKD: No benefit for coronary revascularization in advanced CKD with stable angina
PHILADELPHIA – At 3 years, more than 27% of patients were dead regardless of the coronary artery disease management strategy.
Conference Coverage
RNA inhibitors silence two new targets in dyslipidemia
PHILADELPHIA –
Conference Coverage
The TWILIGHT of aspirin post-PCI for ACS?
PHILADELPHIA –
Conference Coverage
GALILEO, GALILEO 4D: Mixed results in post-TAVR anticoagulation
Conference Coverage
ISCHEMIA trial hailed as practice changing
PHILADELPHIA – The largest-ever RCT of initial invasive versus conservative management of stable ischemic heart disease makes waves.
Conference Coverage
DAPA-HF: Dapagliflozin’s HFrEF efficacy confirmed in nondiabetics
PHILADELPHIA –
Conference Coverage
Weaknesses exposed in valsartan recall
PHILADELPHIA – A population study in Canada exposed incomplete adherence after the valsartan recall of July 2018.
Conference Coverage
Getting high heightens stroke, arrhythmia risks
Cannabis use or abuse among the young was associated with adverse cardiovascular consequences in two studies.
Conference Coverage
Biomarkers predict VTE risk with menopausal oral hormone therapy
CHICAGO – Pretreatment high D-dimer spells 500% increased VTE risk on oral hormone therapy.
Conference Coverage
PCSK9 inhibition isn’t the answer for high Lp(a)
CHICAGO – “The reality is that for now we don’t have any drugs to significantly lower elevated Lp(a),” said Dr. Erik S. Stroes.